Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
Plasma ctHPVDNA Predicts Recurrence of HPV-Associated Oropharyngeal Cancer
02/10/2020
Post-treatment surveillance via plasma ctHPVDNA can help detect the risk for recurrence in patients with HPV-associated OPSCC, according to prospective study findings.
Post-treatment surveillance via plasma ctHPVDNA can help detect the risk for recurrence in patients with HPV-associated OPSCC, according to prospective study findings.
Post-treatment surveillance via...
02/10/2020
Oncology

Advertisement

News
Increased OS With Maximal Resection of CE Tumors in Patients With Glioblastoma
02/06/2020
In a cohort study of patients with newly diagnosed glioblastoma, maximal resection of contrast-enhanced (CE) tumors was tied to increased OS.
In a cohort study of patients with newly diagnosed glioblastoma, maximal resection of contrast-enhanced (CE) tumors was tied to increased OS.
In a cohort study of patients...
02/06/2020
Oncology
News
Treatment Facility Type Impacts OS for Patients With Head and Neck Cancer
02/04/2020
A better understanding of socioeconomic differences and cancer treatment disparities among patients with head and neck cancer may help to improve clinical outcomes.
A better understanding of socioeconomic differences and cancer treatment disparities among patients with head and neck cancer may help to improve clinical outcomes.
A better understanding of...
02/04/2020
Oncology
News
Immunosuppression Risk Factor for Poor Outcomes in Squamous Cell Head and Neck Cancer
01/03/2020
For patients with cutaneous squamous cell carcinoma of the head and neck, immunosuppression is an independent risk factor for worse outcomes.
For patients with cutaneous squamous cell carcinoma of the head and neck, immunosuppression is an independent risk factor for worse outcomes.
For patients with cutaneous...
01/03/2020
Oncology

Advertisement

News
Acupuncture May Prevent Radiation-Induced Xerostomia in Head and Neck Cancer
12/19/2019
Findings from a phase 3 study suggest that acupuncture may be used to prevent radiation-induced xerostomia in patients with head and neck cancer.
Findings from a phase 3 study suggest that acupuncture may be used to prevent radiation-induced xerostomia in patients with head and neck cancer.
Findings from a phase 3 study...
12/19/2019
Oncology
News
Higher Risk for Brain Metastases With Twice vs Once Daily Radiotherapy After Irradiation for SCLC
06/28/2019
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Patients with SCLC who received...
06/28/2019
Oncology
News
Brain Tumor Therapy Tied to Severe Sensorineural Hearing Loss, Difficulty Reading
06/07/2019
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Over time, young patients with...
06/07/2019
Oncology

Advertisement

News
Adult Survivors of Childhood Brain Tumors May Struggle to Live Independently
09/14/2018
Adults who had brain cancer as children may have a harder time living independently and having rich professional and personal lives than people who didn't have these tumors in childhood.
Adults who had brain cancer as children may have a harder time living independently and having rich professional and personal lives than people who didn't have these tumors in childhood.
Adults who had brain cancer as...
09/14/2018
Oncology
News
Nivolumab Plus Ipilimumab Effective Against Melanoma Brain Metastases
08/23/2018
Among people with melanoma whose tumors have spread to the brain, the combination of nivolumab and ipilimumab produces a complete response in 26% of asymptomatic patients.
Among people with melanoma whose tumors have spread to the brain, the combination of nivolumab and ipilimumab produces a complete response in 26% of asymptomatic patients.
Among people with melanoma whose...
08/23/2018
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use